新生儿期接种乙肝疫苗的抗逆转录病毒初治年轻HIV感染者启动抗逆转录病毒治疗后HBV血清学标志物的演变
这项回顾性队列研究纳入2004至2020年间608例曾接受新生儿乙肝疫苗接种的HIV感染者,评估启动含抗HBV活性NRTIs的抗逆转录病毒治疗后HBV血清学标志物变化。中位随访2.8年的492例中,基线三联阴性者发生4例新发HBV感染(0.59/100人年),基线有血清保护者中38例失去抗-HBs(4.46/100人年)并发生4例新发感染(0.47/100人年)。
要点
- 基线时13例(2.1%)HBsAg阳性,312例(51.3%)三联阴性,209例(34.4%)疫苗诱导血清保护,74例(12.2%)抗-HBc阳性。
- 基线抗-HBs滴度≥100 mIU/mL者失去血清保护的风险较低(aHR 0.10,95%CI 0.02-0.42)。
- 随访期间CD4≥500 cells/µL者失去血清保护的风险较低(aHR 0.51,95%CI 0.30-1.00)。
核心结论
- 在曾接受新生儿乙肝疫苗接种的年轻HIV感染者中,尽管使用含抗HBV活性NRTIs的抗逆转录病毒治疗,HBV血清学标志物仍发生演变并出现新发感染。
研究设计与样本
- 回顾性队列研究,纳入2004至2020年间608例曾接受新生儿乙肝疫苗接种的HIV感染者,平均年龄24岁,62.0%启动含替诺福韦的抗逆转录病毒治疗。
主要发现
- 基线时13例(2.1%)HBsAg阳性,312例(51.3%)三联阴性,209例(34.4%)疫苗诱导血清保护,74例(12.2%)抗-HBc阳性伴或不伴抗-HBs。
- 492例接受中位随访2.8年,基线三联阴性者发生4例新发HBV感染(0.59/100人年)。
- 基线有血清保护者中38例随后失去抗-HBs(4.46/100人年),并发生4例新发HBV感染(0.47/100人年)。
- 基线抗-HBs滴度≥100 mIU/mL者失去血清保护的风险较低(aHR 0.10,95%CI 0.02-0.42)。
- 随访期间CD4≥500 cells/µL者失去血清保护的风险较低(aHR 0.51,95%CI 0.30-1.00)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With initiation of antiretroviral therapy (ART) containing nucleos(t)ide reverse-transcriptase inhibitors (NRTIs) with anti-hepatitis B virus (HBV) activity, the evolution of HBV serologic markers among people living with human immunodeficiency virus (PLWH) who were born in the era of nationwide neonatal HBV vaccination is rarely investigated. METHODS: This retrospective cohort study evaluated the changes of HBV serologic markers (hepatitis B surface antigen [HBsAg], antibody to hepatitis B surface antigen [anti-HBs], and antibody to hepatitis B core antigen [anti-HBc]) of PLWH who had undergone neonatal HBV vaccination. Clinical characteristics were analyzed and the incidences of evolution of HBV serologic markers were estimated. RESULTS: Between 2004 and 2020, 608 PLWH (mean age, 24 years) were included and 62.0% initiated tenofovir-containing ART: 13 (2.1%) were HBsAg-positive, 312 (51.3%) tested triple-negative, 209 (34.4%) had vaccine-induced seroprotection against HBV, and 74 (12.2%) tested positive for anti-HBc with or without anti-HBs. Among 492 PLWH who received a median follow-up of 2.8 years, 4 cases of incident HBV infection occurred (0.59 per 100 person-years of follow-up [PYFU]) in PLWH testing triple-negative at baseline despite ART containing NRTIs with anti-HBV activity. Of PLWH with seroprotection against HBV at baseline, 38 subsequently lost anti-HBs (4.46 per 100 PYFU) and 4 cases of incident HBV infection occurred (0.47 per 100 PYFU). PLWH with an anti-HBs antibody titer ≥100 mIU/mL at baseline (adjusted hazard ratio [aHR], 0.10 [95% confidence interval {CI}: .02-.42]) and CD4 ≥500 cells/µL during follow-up (aHR, 0.51 [95% CI: .30-1.00]) were less likely to lose HBV seroprotection. CONCLUSIONS: Among young PLWH who had undergone neonatal HBV vaccination, evolution of HBV serologic markers and incident infections occurred despite ART containing NRTIs with anti-HBV activity.
引用
- Huang YC, Sun HY, Sheng WH, et al. Evolution of Hepatitis B Virus (HBV) Serologic Markers Among Antiretroviral-Naive Young People Living With Human Immunodeficiency Virus Who Had Undergone Neonatal HBV Vaccination and Initiated Antiretroviral Therapy. Clin Infect Dis. 2022. PMID: 34893815. doi:10.1093/cid/ciab1020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。